Skip to content
Screener

PTC Therapeutics PTCT Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.83M+51.6%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$209.82M+41.0%
ALN
Alnylam PharmaceuticalsALNY
$9.15M-16.3%
Biogen logo
BiogenBIIB
$820.9M+2.7%
uniQure logo
uniQureQURE
$2.69M-55.3%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.91B+45.3%
Enterprise value$5.47B+58.8%
P/E7.3×—
P/S7.2×+4.8×

Profitability

See full
Gross margin96%—
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%—
Debt / equity372.3×—
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemMarch 31, 2026December 31, 2025
Operating lease liabilities- noncurrent90,07293,583
Finance lease liabilities- noncurrent—3,000
Liability for sale of future royalties- noncurrent2,022,1892,025,366
Other long-term liabilities13,70413,704
Total liabilities3,049,5693,104,080
Stockholders’ deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025.8180
Additional paid-in capital2,778,0262,748,335

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's other non-current liabilities?
PTC Therapeutics (PTCT) reported other non-current liabilities of $13.7M in Q1 2026.
How has PTC Therapeutics's other non-current liabilities changed year-over-year?
PTC Therapeutics's other non-current liabilities decreased by 38.9% year-over-year, from $22.43M to $13.7M.
What is the long-term trend for PTC Therapeutics's other non-current liabilities?
Over 4 years (2020 to 2025), PTC Therapeutics's other non-current liabilities has grown at a 77.1% compound annual growth rate (CAGR), from $1.39M to $13.7M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about PTC Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude